ASCO Conference Coverage
Featured Articles
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
Read Article
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
Read Article
Latest Articles
June 25, 2019
June 14, 2019
June 12, 2019
June 12, 2019
June 11, 2019
June 06, 2019
June 06, 2019
June 06, 2019
View More
News Commentary
Editor Image
05 Jun, 2019 | by H. Jack West, MD
While in keeping with what we see informally in our clinics, these documented...
View Comment
Editor Image
01 Jun, 2019 | by Tomasz M. Beer, MD
The TITAN study adds apalutamide to a growing number of agents that improve...
View Comment
View More
OBR Blog
Today, four plenary sessions dropped at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting featured... Read more
June 02, 2019
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019

OBR Tweets

Jan 27
William McGivney, PhD: The article (with totally ex-US authors) referred to was published in the British Medical Jo… https://t.co/6reunkPxAW

Jan 27
Howard S. Hochster, MD: Interesting but not overwhelming response rates, especially when compared with pretreated p… https://t.co/KFQMekfkeJ

Jan 25
Daniel Catenacci, MD, of @UChicagoMed elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020… https://t.co/SLFXcH9XHW

Jan 25
Manish Shah, MD, of @WeillCornell on the role of Cyramza in the treatment of gastric and esophageal cancers #GI20 https://t.co/83LT4SouTG

Jan 25
Daniel Catenacci, MD, of @UChicagoMed discusses margetuximab in the treatment of esophageal and gastric cancer #GI20 https://t.co/bKgtxzm0tl

Jan 25
Manish Shah, MD, of @WeillCornell regarding the use of liquid biopsy to diagnose and treat GI cancers #GI20 https://t.co/PgJcHQr2IZ

Jan 25
Sam Klempner, MD, of @harvardmed explains how circulating tumor DNA can be used to help determine therapy #GI20 https://t.co/xZwsm7PSW6

Jan 25
Hani Babiker, MD, of @UAZCancer elaborates on tumor treatment fields applying to GI malignancies #GI20 https://t.co/g8OENPsK7Y

Jan 25
Hani Babiker, MD, of @UAZCancer describes the setting of FDA approval on tumor treatment fields #GI20 https://t.co/Ytzc1MwAGM

Jan 25
Ahmed Kaseb, MD, of @MDAndersonNews on combining cabozantinib with checkpoint inhibitors for treatment of HCC #GI20 https://t.co/dd7RbGGru5